A negative hormone receptor status and receipt of previous cytotoxic chemotherapy were significantly more frequent in patients receiving anti-HER2 therapies owing to the intrinsic molecular features of their breast cancer subtype. This evidence concerns the gene ERBB2 and breast carcinoma.